MICROSAIC SYSTEMS PLC

AGM Information • Jun 25, 2020

National Storage Mechanism | Additional information

RNS Number : 1258R

Microsaic Systems plc

25 June 2020

25 June 2020

Microsaic Systems plc

("Microsaic" or the "Company")

Result of AGM

Microsaic Systems plc (AIM:MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that all resolutions proposed at its Annual General Meeting today were duly passed on a poll, the results of which are set out below:

	Ordinary resolutions	Votes for	% of votes cast	Votes against	% votes cast	Votes withheld
1	To approve the audited accounts of the Company for the year ended on 31 December 2019, together with the Directors' Report and Auditors' Report thereon	329,369,671	100.00	-	-	500
2	To re-appoint Saffery Champness LLP as auditors to the Company, and that the Board be authorised to fix the remuneration of the auditors	329,176,504	99.94	193,667	0.06	-
3	To re-appoint Bevan Metcalf as a Director of the Company	329,370,171	100.00	-	-	-
4	To authorise the Directors to allot equity securities up to an aggregate nominal amount of £380,304	329,176,504	99.94	193,667	0.06	-
	Special resolution	Votes for	% of votes cast	Votes against	% votes cast	Votes withheld
5	To dis-apply statutory pre-emption rights	328,461,504	99.73	908,667	0.27	-

Enquiries:

Microsaic Systems plc	+44 (0) 1483 751 577
Glenn Tracey, CEO
Bevan Metcalf, FD
N+1 Singer (Nominated Adviser & Joint Broker)	+44 (0)20 7496 3000
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)
WH Ireland Limited (Joint Broker)	+44 (0)20 7220 1666
James Joyce (Corporate Finance)
Jasper Berry (Corporate Broking)

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing, and have applications in environmental testing, chemical reaction monitoring, and academic teaching. The Company is working with a range of established global life science OEM partners, distributors and research organisations to co-develop and commercialise new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

Microsaic's core products, the 4500 MiD®, and MiD®ProteinID are robust and compact MS systems, retaining the functionality of larger conventional MS systems, easier to use by non-specialists, consuming less energy and having lower running costs. For more information, please go to www.microsaic.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGFAMITMTBTBAM